Skip to Content
Morningstar

Cochlear Ltd Stock Quote COH

Morningstar Rating
Rating as of

Morningstar's Cochlear Ltd Stock Analysis

Valuation
Currency in AUD
Is it the right time to buy or sell?
Find out with Morningstar Investor
Is it the right time to buy or sell?
Find out with Morningstar Investor

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Emerging Markets Show Promise but Cochlear Shares Remain Expensive

Shane Ponraj, CFA Equity Analyst

Business Strategy and Outlook

| Shane Ponraj, CFA |

With a consistent share of roughly 60% across developed markets, Cochlear is the market leader in cochlear implants. Cochlear implants became the standard of care many years ago for children in developed markets with profound hearing loss or deafness. With this market segment largely penetrated, the company is looking elsewhere for growth. Developed market adults are the next primary focus, and emerging-market children after that.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics - COH

More

Company Profile - COH

Business Description

Cochlear is the leading cochlear implant device manufacturer with around 60% global market share. Developed markets contribute 80% of group revenue where cochlear implants are the standard of care for children with severe to profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, or BAHA, and associated sound processors. In fiscal 2020, 49% of revenue came from the Americas, 35% from EMEA, and 16% from the Asia-Pacific segment.

Contact
1 University Avenue, Macquarie University
Sydney, NSW, 2109, Australia
T +61 294286555
Sector Healthcare
Industry Medical Devices
Most Recent Earnings —
Fiscal Year End Jun 30, 2022
Stock Type —
Employees 4,000

Related News - COH

Stock Analyst Notes

Cochlear Solidifies Its Wide Moat via Oticon Medical Acquisition

<xhtml xmlns="http://cms.morningstar.com/api/v2"/>
Shane Ponraj
Stock Analyst Notes

Disposition of the Implants Business Inevitable Development for Demant

<xhtml xmlns="http://cms.morningstar.com/api/v2"/>
Alex Morozov
Stock Analyst Notes

Developed-Markets Sales Drop as Cochlear’s Operating Costs Increase; Shares Remain Expensive

<xhtml xmlns="http://cms.morningstar.com/api/v2"/>
Shane Ponraj
Stock Analyst Notes

Omicron Could Pose Risk for Cochlear’s Near-Term Recovery; Shares Remain Overvalued

<xhtml xmlns="http://cms.morningstar.com/api/v2"/>
Shane Ponraj
Stock Analyst Notes

Cochlear’s FVE Up 9% Driven by a Stronger U.S. Dollar and Lower Expenses Forecast in the Longer Term

<xhtml xmlns="http://cms.morningstar.com/api/v2"/>
Shane Ponraj
Stock Analyst Notes

Cochlear’s FVE Increased 16% With Emerging Markets Showing More Promise

<xhtml xmlns="http://cms.morningstar.com/api/v2"/>
Shane Ponraj
Stock Analyst Notes

Quick Recovery As Cochlear Benefits From Rescheduled Surgeries in Developed Markets

<xhtml xmlns="http://cms.morningstar.com/api/v2"/>
Mathew Hodge
Stock Analyst Notes

Advanced Bionics’ New Sound Processors Unlikely to Threaten Cochlear; FVE Unchanged

<xhtml xmlns="http://cms.morningstar.com/api/v2"/>
Mathew Hodge
Stock Analyst Notes

Coronavirus Impacts on Cochlear’s Implants Less Than Anticipated; Increase FVE to AUD 138

<xhtml xmlns="http://cms.morningstar.com/api/v2"/>
Mathew Hodge
Stock Analyst Notes

Benefit of Cochlear’s New Products Overshadowed by Coronavirus Curtailment of Surgeries

<xhtml xmlns="http://cms.morningstar.com/api/v2"/>
Nicolette Quinn
Stock Analyst Notes

Cochlear Trading Update in Line With Expectations, No Change to Fair Value Estimate

<xhtml xmlns="http://cms.morningstar.com/api/v2"/>
Nicolette Quinn
Stock Analyst Notes

Corporate Action: Cochlear Raises Equity, Issue Price Comparable to Our Fair Value, Do Not Subscribe

<xhtml xmlns="http://cms.morningstar.com/api/v2"/>
Nicolette Quinn
Stock Analyst Notes

Elective Surgery Deferrals and Legal Case Loss Reduce Cochlear Fair Value, Reduce FVE 5% to AUD 129

<xhtml xmlns="http://cms.morningstar.com/api/v2"/>
Nicolette Quinn
Stock Analyst Notes

Disappointing First-Half Result From Cochlear Confirms Profitable Growth Challenging to Come By

<xhtml xmlns="http://cms.morningstar.com/api/v2"><br/> <br/></xhtml>
Nicolette Quinn
Stock Analyst Notes

Coronavirus Reduces Near-Term Cochlear Implants in China, but Recovery Expected, Maintain FVE

<xhtml xmlns="http://cms.morningstar.com/api/v2"><br/> <br/></xhtml>
Nicolette Quinn
Stock Analyst Notes

Cochlear Pointing to Slower Long-Term Growth, Maintain AUD 135 FVE

<xhtml xmlns="http://cms.morningstar.com/api/v2"><br/></xhtml>
Nicolette Quinn
Stock Analyst Notes

COH Earnings in Line, Investment Thesis Intact, FVE Unchanged at AUD 135

<xhtml xmlns="http://cms.morningstar.com/api/v2"/>
Nicolette Quinn
Stock Analyst Notes

Growth in Cochlear Implants Harder to Come By, Lower FVE to AUD 135

<xhtml xmlns="http://cms.morningstar.com/api/v2"/>
Nicolette Quinn
Stock Analyst Notes

The State of U.S. Healthcare Laws Has a Low Impact on Australian Healthcare Stock Valuations

<xhtml xmlns="http://cms.morningstar.com/api/v2"/>
Nicolette Quinn
Stock Analyst Notes

Soft 1H for Cochlear but Maintaining our AUD 180 FVE

<xhtml xmlns="http://cms.morningstar.com/api/v2"/>
Mathew Hodge